Table 2.
Characteristics of the 20 patients with tuberculosis following ICI exposure
| Patient number | Age, years | Sex | Cancer type | Other comorbidities | Type of ICI | Total ICI cycles received | Interval* (months) | Type of TB | Concomitant corticosteroid | Concomitant immunosuppressant |
| 1 | 73 | Male | Lung cancer | None | Nivolumab | 5 | 5.7 | Pulmonary | No | No |
| 2 | 80 | Male | Lung cancer | Hypertension and chronic lung disease | Nivolumab | 1 | 1.3 | Pulmonary | No | No |
| 3 | 65 | Male | Lung cancer | Chronic lung disease | Nivolumab | 8 | 1.7 | Miliary | No | No |
| 4 | 82 | Male | Lung cancer | Chronic lung disease | Pembrolizumab | 6 | 1.3 | Pulmonary | No | No |
| 5 | 74 | Female | Lung cancer | Hypertension, diabetes and chronic kidney disease | Pembrolizumab | 2 | 0.4 | Meningitis | Yes | No |
| 6 | 81 | Female | Melanoma | Hypertension and chronic lung disease | Pembrolizumab | 2 | 0.7 | Pulmonary | No | No |
| 7 | 65 | Male | Lung cancer | None | Pembrolizumab | 3 | 2.8 | Vertebra | Yes | No |
| 8 | 44 | Female | Lung cancer | Hypertension | Nivolumab | 2 | 1.5 | Pulmonary | No | No |
| 9 | 61 | Male | Lung cancer | Chronic lung disease | Pembrolizumab | 7 | 4.7 | Pericarditis | No | No |
| 10 | 64 | Male | Lung cancer | Hypertension and diabetes | Pembrolizumab | 7 | 5.3 | Pulmonary | Yes | No |
| 11 | 58 | Male | Lung cancer | None | Pembrolizumab | 2 | 2.3 | Pulmonary | No | No |
| 12 | 59 | Male | Lung cancer | Hypertension and chronic lung disease | Pembrolizumab | 1 | 0.9 | Pulmonary | Yes | No |
| 13 | 71 | Male | Lung cancer | Hypertension and chronic lung disease | Nivolumab | 2 | 0.6 | Pulmonary | No | No |
| 14 | 53 | Male | Lung cancer | Chronic lung disease | Nivolumab | 10 | 7.5 | Pulmonary | Yes | No |
| 15 | 54 | Male | Lung cancer | Diabetes and chronic lung disease | Pembrolizumab | 2 | 2.8 | Pulmonary | No | No |
| 16 | 79 | Male | Lung cancer | Chronic lung disease | Pembrolizumab | 3 | 2.0 | Pulmonary | Yes | No |
| 17 | 67 | Female | Lung cancer | Hypertension and diabetes | Nivolumab | 10 | 16.5 | Pulmonary | Yes | No |
| 18 | 78 | Male | Lung cancer | Chronic lung disease | Pembrolizumab | 10 | 13.6 | Pulmonary | No | Yes |
| 19 | 61 | Male | Lung cancer | Hypertension, diabetes and chronic lung disease | Pembrolizumab | 2 | 0.6 | Pulmonary | Yes | No |
| 20 | 83 | Male | Lung cancer | Chronic lung disease | Nivolumab | 10 | 9.1 | Pulmonary | No | No |
*Interval from the first administration of the ICI to the development of TB
ICI, immune checkpoint inhibitor; TB, tuberculosis.